Adenosinereceptorantagonist 1 is a highly selective antagonist for the A2aR adenosinereceptor, exhibiting an IC50 value of 0.29 nM. It demonstrates a remarkable 14-fold selectivity towards the A2aR receptor in comparison to the A2bR receptor.
Adenosinereceptor inhibitor 1 is a highly potent and selective antagonist of adenosinereceptor (AR). It exhibits exceptional affinity for A1 AR, A2A AR, A2B AR, and A3 AR, with respective Ki values of >1000, 68.5, >1000, >1000 nM. This compound demonstrates notable antinociceptive, anti-inflammatory, and peripheral analgesic properties. Therefore, Adenosinereceptor inhibitor 1 holds great promise for investigating cancer and neurodegenerative diseases [1].
BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptorantagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM). In addi
Cyclazosin Free Base is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of furoic acid with the secondary amino group of 6,7-dimethoxy-2-[(4aR,8aS)-octahydroquinoxalin-1-yl]quinazolin-4-amine. It has a role as an adenosine A2A receptorantagonist. It is a member of quinazolines, a member of furans, an aromatic ether, a quinoxaline derivative, an aromatic amide and a monocarboxylic acid amide.